Navigation path

Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues

EU orphan designation number: EU/3/18/2132   
Active ingredient: Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues
Indication: Treatment of beta-thalassaemia intermedia and major
Sponsor: Silence Therapeutics GmbH
Robert-Rössle-Straße 10, 13125 Berlin, Deutschland

  

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
16/01/2019 Orphan designation EMA/OD/0000001845 (2019)226 of 11/01/2019